MYB/MYBL1 改变的儿童型弥漫性低级别胶质瘤的综合分析
该回顾性研究分析了圣犹大儿童研究医院33例MYB或MYBL1改变的儿童型弥漫性低级别胶质瘤,中位随访6.1年,5年无事件生存率为81.3%±8.3%,5年总生存率为96.4%±4.1%。近全或全切患者5年无事件生存率为100%,活检或次全切者为56.6%±15.2%(P<.01)。作者认为手术可切除性是無事件生存的关键决定因素,需进一步研究以确定进展性肿瘤的最佳治疗策略。
要点
- MYB/MYBL1改变儿童型弥漫性低级别胶质瘤预后良好,5年总生存率96.4%±4.1%。
- 近全或全切者5年无事件生存率100%,活检或次全切者56.6%±15.2%(P<.01)。
- 肿瘤位置、组织学或分子改变之间未观察到无事件生存差异。
核心结论
- MYB/MYBL1改变的儿童型弥漫性低级别胶质瘤结局良好,手术可切除性是无事件生存的关键决定因素,进展性肿瘤的最佳治疗策略需进一步研究以明确。
研究设计与样本
- 回顾性研究,纳入圣犹大儿童研究医院治疗或转诊进行病理复核的33例MYB或MYBL1改变的儿童型弥漫性低级别胶质瘤患者,肿瘤标本集中复核并收集临床数据。
主要发现
- 33例患者中男性18例,中位年龄5岁;2例为MYBL1改变,31例为MYB改变,以MYB::QKI融合最常见(n=10,30%)。
- 大多数肿瘤位于大脑半球(n=22,67%);2例(6%)诊断时已有转移;中位随访6.1年。
- 5年无事件生存率为81.3%±8.3%,5年总生存率为96.4%±4.1%。
- 近全或全切患者5年无事件生存率为100%,活检或次全切患者为56.6%±15.2%(P<.01)。
- 基于肿瘤位置、组织学或分子改变未观察到无事件生存差异;进展或转移的肿瘤可能具有不同的甲基化谱并显示MAPK和PI3K/AKT/mTOR通路激活证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric-type diffuse low-grade gliomas (pLGG) harboring recurrent genetic alterations involving MYB or MYBL1 are closely related tumors. Detailed treatment and outcome data of large cohorts are still limited. This study aimed to comprehensively evaluate pLGG with these alterations to define optimal therapeutic strategies. METHODS: We retrospectively reviewed details of pLGG with MYB or MYBL1 alterations from patients treated or referred for pathologic review at St. Jude Children's Research Hospital. Tumor specimens were centrally reviewed, and clinical data were collated. RESULTS: Thirty-three patients (18 male; median age, 5 years) were identified. Two tumors had MYBL1 alterations; 31 had MYB alterations, MYB::QKI fusion being the most common (n = 10, 30%). Most tumors were in the cerebral hemispheres (n = 22, 67%). Two patients (6%) had metastasis at diagnosis. The median follow-up was 6.1 years. The 5-year event-free survival (EFS) rate was 81.3% ± 8.3%; the 5-year overall survival (OS) rate was 96.4% ± 4.1%. Patients receiving a near-total or gross-total resection had a 5-year EFS of 100%; those receiving a biopsy or subtotal resection had a 5-year EFS rate of 56.6% ± 15.2% (P < .01). No difference in EFS was observed based on location, histology, or molecular alterations. However, the tumors that progressed or metastasized may have distinct methylation profiles with evidence of activation of the MAPK and PI3K/AKT/mTOR pathways. CONCLUSIONS: pLGG with MYB/MYBL1 alterations have good outcomes. Our findings suggest that surgical resectability is a crucial determinant of EFS. Further characterization is required to identify optimal treatment strategies for progressive tumors.
引用
- Moreira DC, Qaddoumi I, Spiller S, et al. Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma. Neuro Oncol. 2024. PMID: 38466086. doi:10.1093/neuonc/noae048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。